- Home
- HFBL vs KLRS Comparison
HFBL vs KLRS Comparison
Compare HFBL & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFBL | KLRS |
|---|---|---|
| Founded | 1924 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 46.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HFBL | KLRS |
|---|---|---|
| Price | $17.93 | $9.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 5.4K | ★ 131.3K |
| Earning Date | 01-27-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 35.20 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $21,720,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | ★ 10.10 | N/A |
| 52 Week Low | $12.31 | $2.14 |
| 52 Week High | $19.20 | $12.90 |
Technical Indicators
Market Signals| Indicator | HFBL | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 59.90 |
| Support Level | $17.40 | $8.69 |
| Resistance Level | $17.90 | $10.24 |
| Average True Range (ATR) | 0.47 | 0.89 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 86.83 | 81.41 |
Price Performance
Historical ComparisonAbout HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.